• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

New Johns Hopkins Study Shows Psilocybin Helps Long Term Mental Health

Jason Najum by Jason Najum
August 31, 2023
in Science
Reading Time: 2 mins read
A A
mushrooms

A new study from Johns Hopkins adds further evidence that natural psilocybin use promotes positive long-term effects on well-being measures like emotion regulation, mental flexibility, and reduced neuroticism.

Published by the Johns Hopkins Center for Psychedelic and Consciousness Research, including authors like Roland Griffiths and Matthew Johnson, the study reviewed a sample of over 2,000 individuals intending to use psilocybin outside of clinical research settings.

  • Data was collected 2 weeks before, the day before, 1-3 days after, 2-4 weeks after, and 2-3 months after psilocybin use.
  • Results: A sample of 2,833 respondents. Participants were primarily college-educated men residing in the United States with a prior history of psychedelic use (mean age = 40 years).
  • Participants primarily used dried psilocybin mushrooms (mean dose = 3.1 grams) for “self-exploration” purposes.
  • Quick Lasix For Sale
  • Data collected before and after the psilocybin experience showed reductions in anxiety, depression, and alcohol misuse; increased cognitive flexibility, emotion regulation, spiritual wellbeing, and extraversion; and reduced neuroticism and burnout after psilocybin use.
  • A small percentage of participants (11% at 2-4 weeks and 7% at 2-3 months) experienced persistent negative effects post-psilocybin, such as mood swings and depressive symptoms.

 

From the paper:

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Results from this study, the largest prospective survey of naturalistic psilocybin use to date, support the potential for psilocybin to produce lasting improvements in mental health symptoms and general well-being.

 

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

For more like this, see our interview with Dr. Matthew Johnson:

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: psilocybin
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
mushroom deal

Breaking News: Otsuka Pharmaceutical to Acquire Mindset Pharma

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.